Status:

COMPLETED

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Lead Sponsor:

Genentech, Inc.

Collaborating Sponsors:

SCRI Development Innovations, LLC

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with me...

Eligibility Criteria

Inclusion

  • Adult patients, \>/= 18 years of age
  • Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in patients with metastatic (Stage IV) disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Measurable disease by RECIST criteria
  • Adequate organ system function, as defined by protocol

Exclusion

  • Prior systemic or radiation therapy for metastatic colorectal cancer
  • Adjuvant chemotherapy (and/or chemoradiation) for colorectal cancer within 12 months prior to date of diagnosis of metastatic disease
  • Previously untreated brain metastases
  • History of hypersensitivity to active or inactive excipients of any component of treatment, or known dipyrimidine dehydrogenase deficiency
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  • History of hematemesis or hemoptysis \</= 1 months prior to study enrollment
  • Significant cardiovascular disease or disorder
  • History of abdominal fistula or gastrointestinal perforation \</= 6 months prior to Day 1
  • Positive for hepatitis B, hepatitis C or HIV infection
  • Other active cancers or history of treatment for invasive cancer within the last 5 years, except for non-melanoma skin cancer

Key Trial Info

Start Date :

September 14 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 18 2013

Estimated Enrollment :

194 Patients enrolled

Trial Details

Trial ID

NCT01418222

Start Date

September 14 2011

End Date

March 18 2013

Last Update

May 30 2017

Active Locations (23)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (23 locations)

1

Almac Clinical Technologies

San Francisco, California, United States, 94105

2

Rocky Mountain Cancer Centers; Bone and Marrow Trans

Denver, Colorado, United States, 80218

3

Florida Cancer Specialists; SCRI

Fort Myers, Florida, United States, 33901

4

Florida Hospital Cancer Inst

Orlando, Florida, United States, 32804